Larimar Therapeutics to Participate in Upcoming Investor Conferences

BALA CYNWYD, Pa., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will participate in 1x1 investor meetings at the Wells Fargo Healthcare Conference, taking place September 4-6, 2024 in Boston, MA and the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New York, NY.

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
[email protected]
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
[email protected]
(484) 414-2715

You May Also Be Interested In

• FASHION by Informa’s New York Marketplace: The East Coast’s Most Comprehensive Fashion Commerce Event
• From Homeless to Homeowner: Nonprofit MMI’s Chandra Hawkins-Black Named 2026 NFCC Client of the Year - MMI’s Fourth Win in Six Years
• Pillar Biosciences and Hamilton Expand Automated NGS Library Preparation Method for oncoReveal® Nexus 21 Gene Panel on Hamilton Microlab STAR™ and STARlet™ Liquid Handling Systems